

ISO 12417-1:2015-10 (E)

Cardiovascular implants and extracorporeal systems - Vascular device-drug combination products - Part 1: General requirements

Contents	Page
Foreword	v
Introduction	vi
1 Scope	1
2 Normative references	2
3 Terms and definitions	2
4 Intended performance	6
4.1 General	6
4.2 Classification	6
4.3 Intended clinical location	6
5 Design attributes	6
5.1 General	6
5.2 Drug-containing part of the VDDCP (DCP)	7
5.2.1 General	7
5.2.2 Matrix	7
5.2.3 Active pharmaceutical ingredient (API)	7
6 Materials	8
7 Design evaluation	8
7.1 General	8
7.2 Pre-clinical evaluation	9
7.2.1 Sampling	9
7.2.2 Conditioning of test samples	9
7.2.3 Pre-Clinical in vitro test reports and additional information	10
7.2.4 Pre-clinical in vitro evaluation	10
7.2.5 Preclinical in vivo evaluation	16
7.3 Clinical evaluation	21
7.3.1 Purpose	21
7.3.2 Specific aims	21
7.3.3 Clinical investigation plan	21
7.3.4 Data acquisition	22
7.3.5 Final report	24
7.4 Post-market surveillance	25
8 Manufacturing	25
8.1 General	25
8.2 Raw material reporting and analysis of the API	25
8.3 Raw material analysis and reporting for excipients	26
8.4 VDDCP batch release testing	27
9 Sterilization	27
9.1 Products supplied sterile	27
9.1.1 Testing to support "Sterile" labelling	27
9.2 Products supplied non-sterile	27
9.3 Sterilization residuals	27

10	Packaging	27
10.1	General	27
10.2	Considerations for VDDCPs	28
10.3	Impact of changes in storage and shipping temperatures on VDDCP	28
11	Information supplied by the manufacturer	28
11.1	General	28
11.2	Labelling	28
11.2.1	VDDCP label(s)	28
11.2.2	Record label	29
11.3	Instructions for use (IFU)	29
Annex A (informative) Definitions of potential clinical and technical events		31
Annex B (informative) Local information regarding submission issues for VDDCPs		36
Bibliography		43